Press Releases
March 16, 2023
Revlon Reports Fourth Quarter 2022 Results
Revlon, Inc. (“Revlon” and together with its subsidiaries, the “Company”) today announced its results for the quarter ended December 31, 2022, in its Form 10-K filed with the Securities and Exchange Commission (the “SEC”).
NOVEMBER 5, 2021
Revlon Reports Third Quarter 2021 Results
Results Reflect Continued Top-Line Growth in All Reporting Segments Company Continues to Execute on Strategic Pillars, Driving Highest As Reported Third Quarter EBITDA in Five Years
February 23, 2023
New Vericast Survey Highlights Advertising Paradox
A recent consumer survey by Vericast validated a paradox about personal data that puts marketers in a tough spot. When it comes to digital advertising, consumers want a custom experience – but not at the expense of privacy.
APRIL 5, 2022
Vericast to Invest in Digital Marketing Technologies, Hire 250+ to Support Growth
Investments in machine learning, omnichannel platform, universal coupons and more
JANUARY 13, 2022
Essential Federal Credit Union Supercharges Member Digital Engagement with Vericast’s Account Advisor Powered by Ignite Sales
Account Advisor enables Essential FCU to provide a deeper, consistent, and differentiated member experience
MARCH 2, 2023
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2022.
JANUARY 18, 2022
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
SIGA Technologies, Inc. , a commercial-stage pharmaceutical company focused on the health security market, announced today that it will be participating in Edison Group’s Open House Event, scheduled to take place virtually this month.
JANUARY 10, 2022
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications
MARCH 06, 2023
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of Type 1 diabetes, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided an update on recent corporate developments.
JANUARY 13, 2022
vTv Therapeutics Shares Updated Corporate Presentation
VTVT, a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population.